Effect of Moringa Leaf Capsules on Glycemic Control of Type 2 Diabetic Patients

Sponsor
Islamabad Medical and Dental College (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT06125873
Collaborator
(none)
50
1
2
16.6
3

Study Details

Study Description

Brief Summary

A randomized clinical trial will be done on 50 patients , randomly divided into two groups by lottery method to compare the glycemic control in patients of Type 2 Diabetes Mellitus by the use of Moringa Oleifera (MO) capsules. Patients will be given Moringa Oleifera (MO) capsules for 3 months and follow up will be conducted after 3 months to assess glycemic control.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

Few human studies are reported on Moringa Oleifera (MO), with most trials reported on animals. Based on human studies, the plant has been proposed to decrease glucose levels by increasing insulin secretion and sensitivity and by inhibiting amylase and glucosidase activities proven by animal studies, additional proposed mechanisms of action include increased glucose uptake in the muscle and liver, inhibition of glucose uptake in the intestine, and decreased gluconeogenesis in the liver.

Rationale of this study is to observe the effects of Moringa Oleifera (MO) capsules, a herbal medicine, on lowering Hba1c levels and compare it with the first line drug so that it can be recommended in the guidelines as a supportive treatment option.

A few human studies are reported on the use of Moringa Oleifera (MO), most of trials are reported on animals. In Pakistan no such study is available but people in rural areas take it as a myth to treat different diseases.

Moringa Oleifera (MO) leaves are non-toxic. This has been confirmed by laboratory experiments such as The aqueous extract of leaves was administered orally to 30 male Wistar rats and even in doses of 2000 mg/kg no mortality ensued. Sub-acute toxicity was assessed by administering daily doses of up to 1600 mg kg to male rats, and no signs of serious toxicity were observed on biochemical or haematological tests, or on histopathology of the organs.

According to the International Diabetes Federation, in the year 2022, 26.7% of adults in Pakistan are a victim of diabetes mellitus, making the total number of cases approximately 33,000,000. This alarmingly high number poses not only an enormous risk of health complications but also a huge financial load on patients. A substantial proportion of patients' income is spent on diabetes care. The mean annual direct cost per patient with diabetes was estimated to be 80,000 Rupees. Medications accounted for the largest share (60.4%) of this cost. The WHO has supported the evaluation of medicinal plants and herbs for the management of certain chronic conditions. In recent years there has been exponential growth in the field of herbal medicines and the demand for these is increasing both in developing and developed countries because of their natural origin, fewer side effects and low cost.

The objective of this study is to assess the combined effect of metformin and Moringa Oleifera (MO) capsules on the participants of glycaemic control (Type 2 diabetics), the safety of Moringa Oleifera (MO) capsules by measuring the partcipant's Liver function tests(LFTs) and Renal function tests(RFTs). HbA1c level of ≥ 7.0% will be considered as 'poor glycemic control'.

Pilot testing will be done on 5% of the sample before conducting the whole study.Informed written consent will be taken from the enrolled patients and confidentiality will be maintained throughout the study. A detailed history will be taken focusing on duration and onset, family history, lifestyle and daily activities. Liver Function Tests and Renal Function Tests will be assessed. A questionnaire attached will be used by the investigators for taking participant's history, anthropometric measures, and demographic details. Data will be collected under the supervision of a diabetic specialist. Particpants will be requested to visit ANTH hospital every month to get their lab investigations done and to report side effects if any. Glycated haemoglobin (HbA1c) will be determined by high-performance liquid chromatography before and at the end of the study by a skilled Lab technician in (ANTH). Fasting blood glucose levels will be measured by a glucometer and participants will also be instructed and guided on the first visit to use a glucometer to check and note daily fasting glucose levels. The questions regarding any side effects are included in the questionnaire. There will be no potential risk to the patient, as monitoring of RFTs, LFTs, and Lipid profiles will be done every month. If lab reports are deranged on participant's first visit to the hospital, participant will be excluded from the study. Random distribution of patients will be done through lottery method. Group A will be treated with Tablet Metformin 500mg twice a day and group B with Moringa Oleifera (MO) capsules along with patients usual dose of Tablet Metformin. All the patients will be advised to have proper diet control and lifestyle modifications.

The data will be analyzed with the help of Statistical Package for Social Sciences (SPSS) version 25. Chi-square test will be applied to compare the clinical efficacy, and safety in terms of any side effect between both groups throughout the study period. P-value of <0.05 will be considered significant.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Supportive Care
Official Title:
Effect of Moringa Leaf Capsules on Glycemic Control of Type 2 Diabetic Patients- an Interventional Study
Actual Study Start Date :
Mar 15, 2023
Anticipated Primary Completion Date :
May 1, 2024
Anticipated Study Completion Date :
Aug 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Metformin

Metformin 500mg taken orally twice daily

Drug: Metformin
Moringa + Metformin - Moringa 1 gm and Metformin 500 mg
Other Names:
  • Metformin is a glucose-lowering drug by inhibiting hepatic gluconeogenesis and opposing the action of glucagon.
  • Experimental: "Moringa+Metformin"

    Metformin 500mg taken orally twice daily with Moringa Oliefera (MO) capsule 1g once daily before breakfast

    Drug: Metformin
    Moringa + Metformin - Moringa 1 gm and Metformin 500 mg
    Other Names:
  • Metformin is a glucose-lowering drug by inhibiting hepatic gluconeogenesis and opposing the action of glucagon.
  • Outcome Measures

    Primary Outcome Measures

    1. Moringa leaf powder decreases blood sugar level in type 2 diabetic patients. [3 months]

      Fasting blood glucose tested after 15 days regularly.

    2. It controls blood Glycated hemoglobin level in type 2 diabetic patients. [3 months]

      Glycated Hemoglobin(Hb A1c) tested after 3 months.

    Secondary Outcome Measures

    1. Moringa leaf powder effect on Systolic Blood Pressure [3 months]

      Systolic BP will be measured in mm Hg at the start of study and then after every 3 months

    2. Moringa leaf powder effect on Diastolic Blood Pressure [3 months]

      Diastolic BP will be measured in mm Hg at the start of study and then after every 3 months

    3. Moringa leaf powder effect on body weight of patients [3 months]

      The weight in kg at the start of study and then after every 3 months

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria:• The patients of over age 40 with type 2 diabetes

    • The patients who willingly consent

    Exclusion Criteria:• Patients having Type I diabetes

    • Pregnant women

    • The patients with deranged LFTs and RFTs.

    • Patients having Creatinine levels more than 1.3 mg/dl in man and >1.1mg/dl in female.

    • Patients of Type II diabetes on insulin therapy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Islamabad Medical and Dental College Islamabad Federal Pakistan 44000

    Sponsors and Collaborators

    • Islamabad Medical and Dental College

    Investigators

    • Study Director: Yasiri Niazi, MD, IMDC

    Study Documents (Full-Text)

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Professor Dr. Asma Irfan, Professor and Head of Department, Islamabad Medical and Dental College
    ClinicalTrials.gov Identifier:
    NCT06125873
    Other Study ID Numbers:
    • imdc123
    • No 99/IMDDC/IRB-2022
    First Posted:
    Nov 9, 2023
    Last Update Posted:
    Nov 9, 2023
    Last Verified:
    Nov 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Professor Dr. Asma Irfan, Professor and Head of Department, Islamabad Medical and Dental College
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 9, 2023